A controlled study of the efficacy and safety of mianserin and maprotiline in outpatients with major depression
by
Moller HJ, Riehl T, Dietzfelbinger T, Wernicke T
Psychiatric Clinic,
University of Bonn,
Venusberg, Germany.
Int Clin Psychopharmacol 1991 Winter; 6(3):179-92

ABSTRACT

Efficacy and tolerability of mianserin (60-90 mg/day) or maprotiline (100-150 mg/day) were tested in a 4-week double-blind control group study on 317 depressive outpatients. The patients had to fulfill the criteria of a major depression according to DSM-III. The study was performed by psychiatrists after special rater training. Standardized rating procedures were applied to evaluate depressive symptoms and unwanted effects at three measurement points. A significant improvement was found in both groups, without any statistical differences between mianserin and maprotiline. According to the Clinical Global Impressions (CGI) 65% of the patients in both groups were judged as responders. A good tolerability of both drugs were demonstrated. With respect to anticholinergic side-effects there was a certain advantage in favor to mianserin.

TCAs
SSRIs
Options
Mianserin
Reboxetine
Amineptine
Dumb drugs
TCAs v SSRIs
Norepinephrine
Antidepressant toxicity
Maprotiline versus paroxetine
Maprotiline versus amitriptiline
Maprotiline versus fluvoxamine
Maprotiline versus moclobemide


Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family